LOS ANGELES–(BUSINESS WIRE)–Forcyte Biotechnologies, a tech-enabled drug discovery company targeting diseases of mechanobiology, has secured new funding from Milestone View, Pioneer Fund, Acequia Capital, Y Combinator, Jude Gomila (CEO, Golden), …
Forcyte has been awarded a $1.5M phase 2 SBIR to continue developing functional assays for cellular contractility to support programs in respiratory, hypertension, and many other indications where cellular force …
The collaborative App Note can be requested directly from Molecular Devices. Inquiries may be directed to info@forcytebio.com. Free assay samples are available! Download App Note Here!
Forcyte has been selected as 1 of 8 companies given a presentation space at the Society of Laboratory Automation and Screening annual meeting in Washington D.C. on Feb 4-6. We …
Forcyte Biotechnologies has received a Phase I Small Business Innovative Research (SBIR) Grant from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), part of the …
Forcyte Biotechnologies has received a Phase I Small Business Innovative Research (SBIR) Grant from the National Center for Complementary and Integrative Health (NCCIH), part of the National Institutes of Health …
We are seeking a razor-sharp and self-driven ‘A-player’ trained in and stimulated by biotechnology to join the founding team and lead operations in our LA Biomed location! Great opportunity to …
>3 years of work and development in the Di Carlo Lab has led to a thorough publication describing the broad capabilities and use-cases for the FLECS platform. On February 8, …
Dr. Pushkarsky presented the team’s overall work on FLECS Technology at the annual SBI2 meeting in San Diego back in September 2017. He was happy to have been awarded the …
